Establishing Personalized Blood Protein Reference Ranges Using Noninvasive Microsampling and Targeted Proteomics: Implications for Antidoping Strategies.

blood-doping practices dried blood spots microsampling multiple reaction monitoring quantitative proteomics targeted proteome profile

Journal

Journal of proteome research
ISSN: 1535-3907
Titre abrégé: J Proteome Res
Pays: United States
ID NLM: 101128775

Informations de publication

Date de publication:
24 Apr 2024
Historique:
medline: 24 4 2024
pubmed: 24 4 2024
entrez: 24 4 2024
Statut: aheadofprint

Résumé

To prevent doping practices in sports, the World Anti-Doping Agency implemented the Athlete Biological Passport (ABP) program, monitoring biological variables over time to indirectly reveal the effects of doping rather than detect the doping substance or the method itself. In the context of this program, a highly multiplexed mass spectrometry-based proteomics assay for 319 peptides corresponding to 250 proteins was developed, including proteins associated with blood-doping practices. "Baseline" expression profiles of these potential biomarkers in capillary blood (dried blood spots (DBS)) were established using multiple reaction monitoring (MRM). Combining DBS microsampling with highly multiplexed MRM assays is the best-suited technology to enhance the effectiveness of the ABP program, as it represents a cost-effective and robust alternative analytical method with high specificity and selectivity of targets in the attomole range. DBS data were collected from 10 healthy athlete volunteers over a period of 140 days (28 time points per participant). These comprehensive findings provide a personalized targeted blood proteome "fingerprint" showcasing that the targeted proteome is unique to an individual and likely comparable to a DNA fingerprint. The results can serve as a baseline for future studies investigating doping-related perturbations.

Identifiants

pubmed: 38655860
doi: 10.1021/acs.jproteome.4c00020
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Vincent R Richard (VR)

Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.

Georgia Mitsa (G)

Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.
Division of Experimental Medicine, McGill University, Montréal, Quebec H4A 3J1, Canada.

Azad Eshghi (A)

University of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada.

Daria Chaplygina (D)

Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.

Yassene Mohammed (Y)

Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands.

David R Goodlett (DR)

University of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada.

Rene P Zahedi (RP)

Manitoba Centre for Proteomics and Systems Biology, Winnipeg, Manitoba R3E 3P4, Canada.
Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3P4, Canada.
Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada.
CancerCare Manitoba Research Institute, Winnipeg, Manitoba R3E 0V9, Canada.

Mario Thevis (M)

Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne 50933, Germany.
European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn 50933, Germany.

Christoph H Borchers (CH)

Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.
Division of Experimental Medicine, McGill University, Montréal, Quebec H4A 3J1, Canada.
Gerald Bronfman Department of Oncology, McGill University, Montréal, Quebec H4A 3T2, Canada.
Department of Pathology, McGill University, Montréal, Quebec H4A 3J1, Canada.

Classifications MeSH